Supernus Pharmaceuticals, Inc. (SUPN) · Oct 19, 2026 · Other events
No new info
Supernus scheduled its Q3 earnings release for October 29. The notice confirms timing, but adds no new financial or operational information.
Supernus is expanding from a specialty CNS drugmaker into a broader neuroscience platform after acquiring Sage and agreeing to merge with Indivior, making the upcoming quarter a useful test of commercial execution and integration. The company’s portfolio now spans ADHD, Parkinson’s disease, postpartum depression, epilepsy and other CNS conditions.
This filing only schedules the next information event. Supernus said it will report third-quarter 2026 financial and business results after the market closes on October 29, followed by a 4:30 p.m. Eastern conference call. 〔0〕
There is no earnings read yet. The filing contains no revenue, profit, prescription, product, pipeline, merger, or guidance update, so it cannot support a beat, miss, or change to the standing business story. The meaningful information will arrive with the results, particularly how the Sage products are contributing and whether management provides any update relevant to the pending Indivior combination.
Bottom line: This is a routine calendar notice, not a business development. The real catalyst is Supernus’s October 29 results and management discussion, not today’s filing itself.
Q3 results and business update, October 29
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!